Faculty Opinions recommendation of A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

2016 ◽  
Author(s):  
Parameswaran Hari ◽  
Binod Dhakal
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Phase 2 ◽  
Single Center ◽  
Single Center Study ◽  
Center Study

scholarly journals A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

Blood ◽  
2014 ◽  
Vol 124 (6) ◽  
pp. 899-906 ◽  
Author(s):  
Nikoletta Lendvai ◽  
Patrick Hilden ◽  
Sean Devlin ◽  
Heather Landau ◽  
Hani Hassoun ◽  
...  
Keyword(s):  
Low Dose ◽  
Overall Response Rate ◽  
Response Rate ◽  
Phase 2 ◽  
Single Center ◽  
Single Center Study ◽  
Key Points ◽  
Duration Of Response ◽  
Grade 3 ◽  
Center Study

Key Points Carfilzomib 56 mg/m2 provided a high overall response rate with a remarkable duration of response in patients with R/RMM. Nonhematologic grade 3/4 AEs likely related to carfilzomib treatment included hypertension and heart failure.

Sign in / Sign up

Export Citation Format

Share Document